Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cilastatin

My MS journey: one patient’s search for innovation

David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients.

Blue Latitude Health

- PMLiVE

Merck says it has plenty in the pipe beyond Keytruda

It has the firepower, but is Merck seeking a big deal?

- PMLiVE

Merck & Co adds to immunotherapy again with $773m Tilos buy

Specialises in TGFβ complex-targeting therapies

- PMLiVE

AZ reports stellar results for Lynparza in pancreatic cancer

Plans to file as soon as possible

- PMLiVE

Merck bulks up in cancer with $2.2bn Peloton buy

Another significant bolt-on in oncology

- PMLiVE

Verily unveils next-gen trials alliance with Novartis, Pfizer

New data methods and tech will be used to streamline trials

Patients as partners: The future of clinical trial design?

'Patient-centric' is a term that appears in almost all clinical trial communications - but what does it mean and how do we achieve it?

Life Healthcare Communications

- PMLiVE

Biotech now vital to pipelines – but success rates falling

IQVIA picks out key trends to drive future productivity

Clinical Trial Materials: Getting the basics right

Clinical Trials Materials: Getting the Basics Right

For those unfamiliar with them, clinical trials can be rather bewildering. This presents problems when it comes to recruiting patients — how can we make sure they understand what they...

Cuttsy + Cuttsy

- PMLiVE

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Part of R&D and commercial collaboration with MSD

- PMLiVE

Keytruda adds another NSCLC approval in Europe

Squamous NSCLC completes first-line dominance

- PMLiVE

Gottlieb admonishes industry for clinical trial failings

Calls for faster uptake of novel trial design and methods

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links